Novartis (NVS)
(Delayed Data from NYSE)
$94.36 USD
+1.79 (1.93%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $94.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVS 94.36 +1.79(1.93%)
Will NVS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVS
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) to Undertake Job Cuts in Development Department
Other News for NVS
Novartis Looks To Get Back On Track With Q1 Earnings
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
Tech advances are catalyzing the Health Care sector with improved investor sentiment - SSGA